摘要
目的对糖尿病肾病综合征患者治疗中实施联合治疗的价值进行评价,探讨患者治疗的效果以及SAS评分变化情况。方法选取2020年1月—2021年1月该院收治的100例糖尿病肾病合并高血压患者为研究对象,结合治疗方式不同,将其中50例实施联合治疗的患者作为研究组,其余50例实施常规治疗的患者作为对照组,观察患者治疗有效率、血糖水平、血压水平、SAS评分及生活质量评分。结果研究组患者治疗总有效率为98.00%,高于对照组的86.00%,差异有统计学意义(P<0.05);治疗前两组患者血糖水平、血压指标以及SAS指数比较,差异无统计学意义(P>0.05),治疗后两组上述指标比较,差异有统计学意义(P<0.05);生活质量评分:治疗前两组比较差异无统计学意义(P>0.05),治疗后组间差异有统计学意义(P<0.05)。结论对糖尿病肾病合并高血压患者采用氨氯地平联合厄贝沙坦联合治疗的效果要好于单项治疗,能够满足患者治疗需求,所以在临床治疗指导过程中能够推广。
Objective To evaluate the value of combined therapy in the treatment of patients with diabetic nephrotic syndrome,and to explore the effect of patients'treatment and changes in the SAS score.Methods A total of 100 patients with diabetic nephropathy and hypertension who were admitted in the hospital from January 2020 to January 2021 were selected as the research subjects,combined with different treatment methods,50 of them were treated as the observation group,and the remaining 50 patients were treated with conventional treatment,served as a control group,to study the effectiveness of treatment,blood glucose level,blood pressure level,SAS score and quality of life score.Results The total effective rate of treatment in the study group was 98.00%,which was higher than 86.00% in the control group,and the difference was statistically significant(P<0.05);before treatment,there was no statistically significant difference in blood glucose levels,blood pressure indicators,and SAS score between the two groups(P>0.05),after treatment,the above indicators of the two groups were compared,and the difference was statistically significant(P<0.05);quality of life score:there was no statistically significant difference between the two groups before treatment(P>0.05),and the difference between groups after treatment was statistically significant(P<0.05).Conclusion The combined treatment of amlodipine and irbesartan for patients with diabetic nephropathy and hypertension is better than single treatment,and can meet the treatment needs of patients,so it can be promoted in the process of clinical treatment guidance.
作者
石利芝
SHI Lizhi(Department of Pharmacy,Wuxi People's Hospital Affiliated to Nanjing Medical University,Wuxi,Jiangsu Province,214023 China)
出处
《糖尿病新世界》
2021年第10期190-193,共4页
Diabetes New World Magazine
